Dr. Zhenyu Yue of Mount Sinai School of Medicine discusses two new BAC Lrrk2 mouse models, recently published in Journal of Neuroscience. As The Michael J. Fox Foundation partially funded this ...
Although LRRK2 is considered one of the most promising drug targets for PD, currently we know very little about its biological function and structure, or how LRRK2 mutations affect its functions that ...